clinically isolated syndromes

52
Clinically Isolated Syndromes

Upload: amr-hassan

Post on 15-Apr-2017

256 views

Category:

Health & Medicine


0 download

TRANSCRIPT

Page 1: clinically isolated syndromes

NOTE

To change

the image

on this slide

select the

picture and

delete it

Then click

the Pictures

icon in the

placeholder

to insert

your own

image

Clinically Isolated

Syndromes

NOTE

To change

the image

on this slide

select the

picture and

delete it

Then click

the Pictures

icon in the

placeholder

to insert

your own

image

Amr Hasan MDFEBN Associate Professor of Neurology - Cairo

University

Mental map for diagnosis of MS

3

ClinicalParaclinicalImaging

Typical for MS Fulfills Criteria

Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

Typical for MS not Fulfilling Criteria

ClinicalImaging Follow Up

CIS

Clinically Isolated Syndromes

Definition Clinical features 1- Optic neuritis 2- Spinal cord syndrome 3-Brain stem syndromes 4-Less common CIS

Risk factors for conversion to MS 1-Demographic environmental and genetic factors 2-Abnormal MRI imaging 3- Biomarkers 4-OCT

Management 1- Acute treatment 2- Disease modifying therapy 3- Vitamin D supplementation

5

Definition

CIS definition

6

bull A first neurologic symptom episode ATTACK of an acute inflammatory demyelinating event in the central nervous system lasting at least 24 hours in the absence of fever or infection (Polman et al 2011)

bull This definition also provides No DIS nor DIT by MRI Brain and Cervical Cord

bullPolman CH Reingold SC Banwell B Clanet M Cohen JA Filippi M Fujihara K Havrdova E Hutchinson M Kappos L Lublin FD Montalban X OConnor P Sandberg-Wollheim M Thompson AJ Waubant E Weinshenker B Wolinsky JS Diagnostic criteria for multiple sclerosis 2010 revisions to the McDonald criteria Ann Neurol 2011 Feb 69(2)292-302

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 2: clinically isolated syndromes

NOTE

To change

the image

on this slide

select the

picture and

delete it

Then click

the Pictures

icon in the

placeholder

to insert

your own

image

Amr Hasan MDFEBN Associate Professor of Neurology - Cairo

University

Mental map for diagnosis of MS

3

ClinicalParaclinicalImaging

Typical for MS Fulfills Criteria

Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

Typical for MS not Fulfilling Criteria

ClinicalImaging Follow Up

CIS

Clinically Isolated Syndromes

Definition Clinical features 1- Optic neuritis 2- Spinal cord syndrome 3-Brain stem syndromes 4-Less common CIS

Risk factors for conversion to MS 1-Demographic environmental and genetic factors 2-Abnormal MRI imaging 3- Biomarkers 4-OCT

Management 1- Acute treatment 2- Disease modifying therapy 3- Vitamin D supplementation

5

Definition

CIS definition

6

bull A first neurologic symptom episode ATTACK of an acute inflammatory demyelinating event in the central nervous system lasting at least 24 hours in the absence of fever or infection (Polman et al 2011)

bull This definition also provides No DIS nor DIT by MRI Brain and Cervical Cord

bullPolman CH Reingold SC Banwell B Clanet M Cohen JA Filippi M Fujihara K Havrdova E Hutchinson M Kappos L Lublin FD Montalban X OConnor P Sandberg-Wollheim M Thompson AJ Waubant E Weinshenker B Wolinsky JS Diagnostic criteria for multiple sclerosis 2010 revisions to the McDonald criteria Ann Neurol 2011 Feb 69(2)292-302

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 3: clinically isolated syndromes

Mental map for diagnosis of MS

3

ClinicalParaclinicalImaging

Typical for MS Fulfills Criteria

Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

Typical for MS not Fulfilling Criteria

ClinicalImaging Follow Up

CIS

Clinically Isolated Syndromes

Definition Clinical features 1- Optic neuritis 2- Spinal cord syndrome 3-Brain stem syndromes 4-Less common CIS

Risk factors for conversion to MS 1-Demographic environmental and genetic factors 2-Abnormal MRI imaging 3- Biomarkers 4-OCT

Management 1- Acute treatment 2- Disease modifying therapy 3- Vitamin D supplementation

5

Definition

CIS definition

6

bull A first neurologic symptom episode ATTACK of an acute inflammatory demyelinating event in the central nervous system lasting at least 24 hours in the absence of fever or infection (Polman et al 2011)

bull This definition also provides No DIS nor DIT by MRI Brain and Cervical Cord

bullPolman CH Reingold SC Banwell B Clanet M Cohen JA Filippi M Fujihara K Havrdova E Hutchinson M Kappos L Lublin FD Montalban X OConnor P Sandberg-Wollheim M Thompson AJ Waubant E Weinshenker B Wolinsky JS Diagnostic criteria for multiple sclerosis 2010 revisions to the McDonald criteria Ann Neurol 2011 Feb 69(2)292-302

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 4: clinically isolated syndromes

Clinically Isolated Syndromes

Definition Clinical features 1- Optic neuritis 2- Spinal cord syndrome 3-Brain stem syndromes 4-Less common CIS

Risk factors for conversion to MS 1-Demographic environmental and genetic factors 2-Abnormal MRI imaging 3- Biomarkers 4-OCT

Management 1- Acute treatment 2- Disease modifying therapy 3- Vitamin D supplementation

5

Definition

CIS definition

6

bull A first neurologic symptom episode ATTACK of an acute inflammatory demyelinating event in the central nervous system lasting at least 24 hours in the absence of fever or infection (Polman et al 2011)

bull This definition also provides No DIS nor DIT by MRI Brain and Cervical Cord

bullPolman CH Reingold SC Banwell B Clanet M Cohen JA Filippi M Fujihara K Havrdova E Hutchinson M Kappos L Lublin FD Montalban X OConnor P Sandberg-Wollheim M Thompson AJ Waubant E Weinshenker B Wolinsky JS Diagnostic criteria for multiple sclerosis 2010 revisions to the McDonald criteria Ann Neurol 2011 Feb 69(2)292-302

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 5: clinically isolated syndromes

5

Definition

CIS definition

6

bull A first neurologic symptom episode ATTACK of an acute inflammatory demyelinating event in the central nervous system lasting at least 24 hours in the absence of fever or infection (Polman et al 2011)

bull This definition also provides No DIS nor DIT by MRI Brain and Cervical Cord

bullPolman CH Reingold SC Banwell B Clanet M Cohen JA Filippi M Fujihara K Havrdova E Hutchinson M Kappos L Lublin FD Montalban X OConnor P Sandberg-Wollheim M Thompson AJ Waubant E Weinshenker B Wolinsky JS Diagnostic criteria for multiple sclerosis 2010 revisions to the McDonald criteria Ann Neurol 2011 Feb 69(2)292-302

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 6: clinically isolated syndromes

CIS definition

6

bull A first neurologic symptom episode ATTACK of an acute inflammatory demyelinating event in the central nervous system lasting at least 24 hours in the absence of fever or infection (Polman et al 2011)

bull This definition also provides No DIS nor DIT by MRI Brain and Cervical Cord

bullPolman CH Reingold SC Banwell B Clanet M Cohen JA Filippi M Fujihara K Havrdova E Hutchinson M Kappos L Lublin FD Montalban X OConnor P Sandberg-Wollheim M Thompson AJ Waubant E Weinshenker B Wolinsky JS Diagnostic criteria for multiple sclerosis 2010 revisions to the McDonald criteria Ann Neurol 2011 Feb 69(2)292-302

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 7: clinically isolated syndromes

7

Clinical features

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 8: clinically isolated syndromes

ON

TM

BS

8

Clinically Isolated Syndrome (CIS)

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 9: clinically isolated syndromes

bull Hemiparesis or homonymous hemianopia that

may be mistaken for an acute stroke

bull Cognitive dysfunction

bull Seizures attributable to a demyelinating lesion in

the cerebral cortex

Clinically Isolated Syndrome (CIS) less common

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 10: clinically isolated syndromes

10

ONSET Could be subacute (Miller et al 2012) after which patients may progress to MS without showing evidence of relapses TYPES bull Monofocal episode single neurologic sign or symptom bull Multifocal episode more than one sign or symptom

bullMiller DH Chard DT Ciccarelli O clinically isolated syndromes Lancet Neurol 2012 Feb11(2)157-69

Clinically Isolated Syndrome (CIS)

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 11: clinically isolated syndromes

bullMonocular

(Central Vision loss)

bullPain

(eye movement)

bullAltered colour vision

bullUhthoffrsquos symptom

bullFlashes

Optic Neuritis Common Symptoms

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 12: clinically isolated syndromes

Multiple Sclerosis amp Eye problems | 25082016 12

Optic Neuritis Common Symptoms

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 13: clinically isolated syndromes

13

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 14: clinically isolated syndromes

14

An Egyptian Patient

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 15: clinically isolated syndromes

bull Decreased visual acuity

bull VF defect

(CentralAltitudinal 29 )

bull Dyschromatopsia

bull Afferent Pupil Defect (RAPD)

bull Optic disc swelling 35

bull Abnormal Contrast

Sensitivity

bull Abnormal VEP

bull Altered Flicker Perception

bull Altered depth perception

bull Optic disc pallor

Optic Neuritis Physical signs

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 16: clinically isolated syndromes

Optic Neuritis Optic Disc

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 17: clinically isolated syndromes

17

Optic Neuritis VF defect

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 18: clinically isolated syndromes

Mental map for diagnosis of ON

18

Optic Neuritis (ON)

ON Typical for MS MRI Fulfills Criteria

ON Atypical for MS Red Flags Present

Work Up for Alternative Diagnoses

ClinicalImaging Follow Up

Alternative Diagnosis Established

Further clinicalimaging typical for MS

MS Diagnosis

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 19: clinically isolated syndromes

19 19

Typical

bull Acute or subacute attack

bull Mostly young adults (age 20-55 y)

bull Unilateral visual acuity loss

bull Improvement withwithout treatment

bull Continued improvement after corticosteroid withdrawn

bull Mild pain that worsens with eye movement

bull The optic disc appears normal or mildly swollen

bull Variable visual field defects may occur

bull Altered perception of motion (the pulfrich phenomenon)

bull Vision blurs when body temperature rises (Uhthoffrsquos phenomenon)

bull Bright fleeting flashes of light (phosphenes)

Atypical

bull Progressive disease

bull Age group lt 12 and gt 50 y

bull Bilateral visual loss bull No spontaneous visual improvement

bull Deterioration after corticosteroid are discontinued

bull Following loss of vision painless to severe pain

bull Severe swelling and hemorrhage in optic disc

bull Variable signs and symptoms depending on etiology

Optic Neuritis Typical Vs Atypical

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 20: clinically isolated syndromes

bull AION (Ischemic Optic Neuropathy)

bull Vasculitic Disorders (ie SLE)

bull Hereditary (ie Leberrsquos)

bull ToxicNutritional (ETOH)

bull Infectious (ieBartonella Lyme)

bull Inflammatory (ie Sarcoid)

bull NeoplasticParaneoplastic (ie lymphoma)

bull Compressive (ieTumours Graversquos orbitopathy)

bull Multiple Evanescent White Dot Syndrome [MEWDS]

bull Acute Idiopathic Blind Spot Enlargement Syndrome [AIBSE])

Optic Neuritis DD

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 21: clinically isolated syndromes

bull NMO

bull CRION

bull ADEM

bull anti-Myelin oligodendrocyte glycoproteinndashassociated

(MOG) optic neuritis

Optic Neuritis DD

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 22: clinically isolated syndromes

TM

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 23: clinically isolated syndromes

23

TM

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 24: clinically isolated syndromes

24

NMO

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 25: clinically isolated syndromes

25

Atypical for MS

bull Hyperacute onset or insidiously progressive

bull Complete transverse myelitis bull Sharp sensory level bull Radicular pain bull Areflexia bull Failure to remit

Isolated Spinal

Cord Syndrome

Typical for MS

bull Evolution over hours to days bull Partial myelitis bull Purely sensory bull Deafferented upper limb bull Lhermittersquos sign bull Partial Brown-Sequard bull Spontaneous remission

Brain and spinal cord MRI

Low risk for MS (20) High risk for MS (60-90) Review McDonald criteria

bull Compression eg intervertebral disc tumor bull Ischemiainfarction bull Other inflammatory eg neuromyelitis optica

sarcoid lupus Sjogrenrsquos bull Infection eg syphilis lyme viral tuberculosis bull Toxicnutritionalmetabolic Eg B12 deficiency

nitrous oxide toxicity copper deficiency bull Arteriovenous malformation bull Non-cord ldquomimicsrdquo eg Guillain-Barre

syndrome Myasthenia gravis

Consider other

diagnosis MRI clearly indicates a non-

MS diagnosis eg spinal cord

compression Abnormal

Lesions consistent with demyelination

Normal

MRI CSF neurophysiological serologic and other studies as

appropriate

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 26: clinically isolated syndromes

26

Atypical for MS bull Hyperacute onset bull vascular territory signs eg lateral medullary syndrome bull agegt50 bull isolated trigeminal neuralgia fluctuating ocularbulbar

weakness bull non-remitting fever meningism

Isolated Brain

Stem Syndrome

Typical for MS bull Internuclear opthalmoplegia bull 6th nerve palsy bull multifocal signs eg facial

sensory loss and vertigo or hearing loss

Brain and spinal cord MRI

Low risk for MS (20)

High risk for MS (60-90) Review McDonald criteria

bull Ischemichemorrhagic (cavernous angioma)

bull Infiltrative bull Inflammatory (Sarcoid lupus) bull Infection (Syphilis listeria lyme viral) bull Toxic bull Nutritional bull Central pontine myelinolysis bull Neuromuscular (myasthenia gravis)

Consider other

diagnosis

MRI clearly indicates a non-

MS diagnosis eg Hge

Abnormal Lesions consistent

with demyelination

Normal

MRI CSF OCT neurophysiological serologic and other studies as appropriate

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 27: clinically isolated syndromes

27

Risk factors for

conversion to MS

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 28: clinically isolated syndromes

bull Younger age of onset

bull Cognitive impairment

bull Vitamin D deficiency

bull Smoking

bull Increased EBV encoded nuclear antigen

Demographic and environmental risk factors

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 29: clinically isolated syndromes

29

A Biomarkers for Multiple SclerosisWHY

BIOMARKERS

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 30: clinically isolated syndromes

30

GENETICIMMUNOGENETIC

bull Biomarkers specified via genomics and immunogenetic

techniques

LABORATORY

bull All other biomarkers that can be measured in body fluids

IMAGING

bull Biomarkers provided by imaging techniques

BIOMARKERS

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 31: clinically isolated syndromes

31

A GENETIC AND IMMUNOGENETIC

BIOMARKERS

BIOMARKERS

HLA-DRB11501 TOB-1 Apo lipoprotein-E

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 32: clinically isolated syndromes

32

B LABORATORY BIOMARKERS

BIOMARKERS

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 33: clinically isolated syndromes

33

I Biomarkers of Immunological Activation

II Biomarkers of Neuroprotection

III Biomarkers of BBB disruption

IV Biomarkers of demyelination

V Biomarkers of Oxidative Stress

VI Biomarkers of Axonal Damage

VII Biomarkers of Glial Activation Dysfunction

VIII Biomarkers of Remyelination Repair

IX Biomarkers of Therapeutic Response

X Prognostic Biomarkers

XI Emering biomarkers

B Laboratory Biomarkers

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 34: clinically isolated syndromes

34

IV

VI

VII

VIII

III

I

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 35: clinically isolated syndromes

35

BIOMARKERS

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 36: clinically isolated syndromes

36

C IMAGING BIOMARKERS

BIOMARKERS

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 37: clinically isolated syndromes

BIOMARKERS

CLINICAL OCB MRI

37

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 38: clinically isolated syndromes

38

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 39: clinically isolated syndromes

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Wait till CDMS

DMT

Normal [conversion rate 20] (2)

Follow up

39

Conversion of CIS to CDMS

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 40: clinically isolated syndromes

40

Conversion of CIS to CDMS

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 41: clinically isolated syndromes

Mar Tintore et al Brain 20151381863-1874

copy The Author (2015) Published by Oxford University Press on behalf of the Guarantors of Brain All rights reserved For Permissions please email journalspermissionsoupcom

Conversion of CIS to CDMS

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 42: clinically isolated syndromes

42

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 43: clinically isolated syndromes

43

Management

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 44: clinically isolated syndromes

Acute treatment

44

CIS

IV methylprednisolone PE

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 45: clinically isolated syndromes

PLEASE

ORAL STEROIDS FOR ON

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 46: clinically isolated syndromes

46

The ONTT was a prospective randomized multicenter placebo-

controlled clinical trial designed to compare the benefits of

treatment with

(1) intravenous methylprednisolone (IVMP) (250 mg administered

every 6 h for 3 days followed by oral prednisone [1 mgkgday]

for 11 days)

(2) oral prednisone (1 mgkgday) or

(3) oral placebo in 457 patients with acute optic neuritis

Beck RW Cleary PA Anderson MM Jr Keltner JL Shults WT Kaufman DI A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis The Optic Neuritis Study Group N Engl J Med 1992 Feb 27 326(9)581-8

PLEASE

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 47: clinically isolated syndromes

bull The ONTT showed that treatment with standard-dose oral

prednisone was associated with an increased rate of new attacks

of optic neuritis

bull After 5 years the recurrence rate was found to be higher in the

oral prednisone (1 mgkg) group (41) than in those who

received IVMP or oral placebo (25)

47

1 Costello F Burton JM An approach to optic neuritis the initial presentation Expert Rev Ophthalmol 2013 8(6)539ndash551 2 Shams PN Plant GT Optic neuritis a review Int MS J 2009 Sep 16(3)82-9

PLEASE

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 48: clinically isolated syndromes

Kasr Alaini Protocol of Manangement of CIS

48

MRI brain and cervical cord (1) with Gd

Abnormal [conversion rate 80] (2)

Offer DMT (3)

Normal [conversion rate 20] (2)

Positive radiology andor CSF Negative results

Follow up Clinical (q 3 mo) and Radiological (q 6m or whenever indicated)

Offer DMT

Comprehensive Approach

1- Exclude mimics 2- Further assessment (fMRI (DTI) CSF analysis cognitive assessment (4)) 3- Neurophysiological

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 49: clinically isolated syndromes

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

49

bull Rovira A Tintore M Spinal cord MRI should always be performed in clinically isolated syndrome patients No Mult Scler 2014 20(13) 1686-7

bull Barkhof F Spinal cord MRI should always be performed in clinically isolated syndrome patients Yes Mult Scler 2014 20(13) 1688-9

bull Hutchinson M Spinal cord MRI should always be performed in clinically isolated syndrome patients Commentary Mult Scler 2014 20(13) 1690-1

bull Brownlee W Miller D Clinically isolated syndromes and the relationship to multiple sclerosis J Clin Neurosci 2014 Dec21(12)2065-2071

bull Reuter F Zaaraoui W Crespy L Faivre A Rico A Malikova I Soulier E Viot P Ranjeva J Pelletier J Audoin B Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis J Neurol Neurosurg Psychiatry 2011821157-9

bull Loitfelder M Fazekas F Petrovic K Fuchs S Ropele S Wallner-Blazek M Jehna M Aspeck E Khalil M Schmidt R Neuper C Enzinger C Reorganization in cognitive networks with progression of multiple sclerosis insights from fMRI Neurology 2011 Feb 876(6)526-33

REFERENCES FOR THE CHART

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 50: clinically isolated syndromes

Kasr Alaini Protocol of Manangement of Multiple Sclerosis

50

bull Jacobs L D et al Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group N Engl J Med 343 898ndash904 (2000)

bull Kappos L et al Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurolog 67 1242ndash1249(2006)

bull Comi G et al Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized double-blind placebo-controlled trial Lancet 374 1503ndash1511 (2009)

bull Comi G et al Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) a phase 3 randomized controlled trial Lancet Neurol 11 33ndash41 (2012)

bull Morrissey S P et al The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis A 5-year follow-up study Brain 116 135ndash146 (1993)

bull Brex P A et al A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 158ndash164 (2002)

Studies that support treatment of CIS patients

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 51: clinically isolated syndromes

bull A small randomized control trial conducted by Derakhshandi et al 2013 suggested that supplementation with cholecalciferol 50000 units weekly in patients with optic neuritis who were vitamin D deficient reduced the risk of conversion to MS and had favourable effects on a number of MRI outcomes

bull The PreVANZ study being conducted in Australia and New Zealand is a randomised double-blind controlled trial investigating three different doses of vitamin D versus placebo in patients with CIS irrespective of baseline vitamin D levels Results are expected in 2017

Vitamin D supplementation

THANK YOU

Page 52: clinically isolated syndromes

THANK YOU